UCB announced that it will present six abstracts in hidradenitis suppurativa (HS) at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA), October 13-15 in Phoenix, Arizona. Data and analyses in HS will be presented across two oral presentations and four posters. An oral presentation will showcase 16-week data from the BE HEARD I and BE HEARD II Phase 3 studies evaluating the impact of bimekizumab on pain in moderate-to-severe HS.

In a second oral presentation, 48-week data evaluating the impact of bimeKizumab on health-related quality of life will be shared. These differences compound the existing health inequity in HS. In the U.S., the efficacy and safety of bimekizumib have not been established for any indication and it is not approved by the U.S. Food and Drug Administration.

UCB-sponsored data presentations at SHSA 2023: Bimekizumab in Moderate to Severe Hidradenitis Suppuriva: 48-Week HiSQoL data from BE HEARD I & II. Bimekizumab Impact on Pain in Moderate to Severe HIDradenitis Suppurativa: Week 16 Results from BE HEARD I &II. Orenstein LAV, Shi V, Lev-Tov H, Prens E, Podda M, Fujita H, Lambert J, Muller E, Szepietowski JC.

Bimekizumib in Black/African-American Patients with moderate to Severe Hid radenitis Suppurativa in BE HEARD I & II Mayo T, Chovatiya R, Shi V, Naik HB, Benhadou F, Costanzo A, Davis L, Zouboulis C Poster; Bimekizumab In Patients with Moderate to Severe Hid Radenitis Suppurativa by Subgroup: Week 16 Data from BE HEARD I & 2 Naik HB, Hsiao J, Porter M, Reguiai Z, Martorell A, Frew JW, Pansar I, Rolleri R, Tilt N, Lambert J, Lambert J, Lambert J., Kirby B, Kirby B, Dokhe P, Rolleri R, Davis L, Daveluy Poster.